Masaki Nakamura1, Shun-Ichiro Kageyama2, Masahide Seki3, Ayako Suzuki3, Masayuki Okumura2, Hidehiro Hojo2, Atsushi Motegi2, Tetsuo Akimoto2. 1. Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Chiba, Japan; masanaka@east.ncc.go.jp. 2. Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Chiba, Japan. 3. Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba, Japan.
Abstract
BACKGROUND/AIM: To investigate the usefulness of cell-free DNA (cfDNA) in patients with oligometastasis. PATIENTS AND METHODS: This study included oligometastatic colorectal cancer (CRC) patients who underwent ablative irradiation using stereotactic body radiotherapy or proton beam therapy for metastatic lesions at a single institution. cfDNA was purified from the plasma of pretreated patients and gene mutations were analyzed by next-generation sequencing. Progression-free survival (PFS) was statistically compared according to gene mutation, clonality or allele frequency. RESULTS: A total of 20 patients were analyzed. Mutations were detected in the following genes; TP53 (45%), APC (40%), KRAS (15%), PIK3CA (15%), NF1 (5%), BRCA1 (5%), ERBB2 (5%), FBXW7 (5%), KIT (10%), and HRAS (10%). Patients with multi-clonality of gene mutation showed tendency for poor PFS (p=0.07). Among 7 patients whose metastatic site was the lung, those with no cfDNA detected had significantly better PFS than those with cfDNA (p=0.02). CONCLUSION: cfDNA profiles could be predictive tools for early recurrence of oligometastatic CRC patients after ablative radiotherapy.
BACKGROUND/AIM: To investigate the usefulness of cell-free DNA (cfDNA) in patients with oligometastasis. PATIENTS AND METHODS: This study included oligometastatic colorectal cancer (CRC) patients who underwent ablative irradiation using stereotactic body radiotherapy or proton beam therapy for metastatic lesions at a single institution. cfDNA was purified from the plasma of pretreated patients and gene mutations were analyzed by next-generation sequencing. Progression-free survival (PFS) was statistically compared according to gene mutation, clonality or allele frequency. RESULTS: A total of 20 patients were analyzed. Mutations were detected in the following genes; TP53 (45%), APC (40%), KRAS (15%), PIK3CA (15%), NF1 (5%), BRCA1 (5%), ERBB2 (5%), FBXW7 (5%), KIT (10%), and HRAS (10%). Patients with multi-clonality of gene mutation showed tendency for poor PFS (p=0.07). Among 7 patients whose metastatic site was the lung, those with no cfDNA detected had significantly better PFS than those with cfDNA (p=0.02). CONCLUSION: cfDNA profiles could be predictive tools for early recurrence of oligometastatic CRCpatients after ablative radiotherapy.
Authors: Igor Tsaur; Roman A Blaheta; Robert Dotzauer; Cristian Mirvald; Jonathan Olivier; Cristian Surcel; Maximilian P Brandt; Giorgio Gandaglia; Ioanel Sinescu Journal: World J Urol Date: 2022-10-02 Impact factor: 3.661
Authors: Hamza AlGhamdi; Jennifer Dhont; Mohammad Krayem; Pauline De Bruyn; Benedikt Engels; Dirk Van Gestel; Robbe Van den Begin Journal: Cancers (Basel) Date: 2022-04-18 Impact factor: 6.575
Authors: Jun Gong; Andrew Hendifar; Alexandra Gangi; Karen Zaghiyan; Katelyn Atkins; Yosef Nasseri; Zuri Murrell; Jane C Figueiredo; Sarah Salvy; Robert Haile; Megan Hitchins Journal: Cancers (Basel) Date: 2021-09-10 Impact factor: 6.639